SRX Global Acquires Stake In Vistagen Therapeutics; Deal Terms Were Undisclosed
The Company views Vistagen shares as undervalued and welcomes constructive engagement with its leadership team and Board of Directors to discuss ideas on how to unlock shareholder value.
SRX Global bought some shares of Vistagen Therapeutics because it thinks the company's stock price is too low right now. When a big investor believes in a company like this, it can be a signal that people should pay attention to whether the company might do better in the future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.